Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes.
Treatment of epilepsy or bipolar disorder with valproic acid (VPA) induces weight gain and increased serum levels for the satiety hormone, leptin, through an unidentified mechanism. In this study we tested the effects of VPA, a short-chain branched fatty acid (C8:0), on leptin biology and fatty acid metabolism in 3T3-L1 adipocytes. VPA significantly reduced leptin secretion in a dose-dependent manner. Because fatty acid accumulation has been hypothesized to block leptin secretion, we tested the effect of VPA on fatty acid metabolism. Using 14C-radiolabeled VPA, we found that the 14C was mainly incorporated into triacylglycerol. VPA did not alter lipogenesis from acetate, nor did it change the amount of intracellular free fatty acids available for triacylglycerol synthesis. Decreased leptin secretion was accompanied by a reduction in leptin mRNA, even though VPA treatment did not alter the protein levels for known transcription factors affecting leptin transcription including: CCAAT/enhancer binding protein-alpha, peroxisome proliferator-activated receptor-gamma, or steroid regulatory element binding protein 1a. VPA altered levels of leptin mRNA independent of de novo protein synthesis without affecting leptin mRNA degradation. This report demonstrates that VPA decreases leptin secretion and mRNA levels in adipocytes in vitro, suggesting that VPA therapy may be associated with altered leptin homeostasis contributing to weight gain in vivo.
Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.
Diane C
DC
Lagace
Roger S
RS
McLeod
Mark W
MW
Nachtigal
D041721:3T3-L1 Cells; D017667:Adipocytes / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D000818:Animals; D000927:Anticonvulsants / Q000493:pharmacokinetics*; D022763:CCAAT-Enhancer-Binding Protein-alpha / Q000235:genetics; D022762:CCAAT-Enhancer-Binding Proteins / Q000235:genetics; D002250:Carbon Radioisotopes; D003513:Cycloheximide / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000235:genetics; D004734:Energy Metabolism / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D005947:Glucose / Q000493:pharmacokinetics; D020738:Leptin / Q000235:genetics* / Q000378:metabolism; D050356:Lipid Metabolism; D051379:Mice; D047495:PPAR gamma / Q000235:genetics; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051780:Sterol Regulatory Element Binding Protein 1; D014157:Transcription Factors / Q000235:genetics; D014635:Valproic Acid / Q000493:pharmacokinetics*
D000927:Anticonvulsants; D022763:CCAAT-Enhancer-Binding Protein-alpha; D022762:CCAAT-Enhancer-Binding Proteins; D002250:Carbon Radioisotopes; D004268:DNA-Binding Proteins; D020738:Leptin; D047495:PPAR gamma; D011500:Protein Synthesis Inhibitors; D012333:RNA, Messenger; C497388:Srebf1 protein, mouse; D051780:Sterol Regulatory Element Binding Protein 1; D014157:Transcription Factors; D014635:Valproic Acid; D003513:Cycloheximide; D005947:Glucose